PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 93 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,705,847 | -33.8% | 1,181,256 | +9.7% | 0.00% | -33.3% |
| Q2 2023 | $29,751,831 | +39.7% | 1,077,184 | +16.3% | 0.00% | 0.0% |
| Q1 2023 | $21,297,847 | +221775.7% | 925,993 | +5.2% | 0.00% | +200.0% |
| Q4 2022 | $9,599 | -99.9% | 879,891 | +6.3% | 0.00% | 0.0% |
| Q3 2022 | $6,975,000 | +7.3% | 827,456 | +0.7% | 0.00% | 0.0% |
| Q2 2022 | $6,501,000 | -67.0% | 821,921 | -1.3% | 0.00% | -50.0% |
| Q1 2022 | $19,723,000 | -25.9% | 832,921 | +7.0% | 0.00% | -33.3% |
| Q4 2021 | $26,610,000 | +106.0% | 778,081 | +6.7% | 0.00% | +50.0% |
| Q3 2021 | $12,916,000 | -59.7% | 728,930 | +2.1% | 0.00% | -50.0% |
| Q2 2021 | $32,037,000 | +91.6% | 713,838 | +10.6% | 0.00% | +33.3% |
| Q1 2021 | $16,723,000 | +63.2% | 645,679 | +27.0% | 0.00% | +50.0% |
| Q4 2020 | $10,247,000 | +19.4% | 508,301 | +15.8% | 0.00% | 0.0% |
| Q3 2020 | $8,584,000 | +32.0% | 439,114 | +19.2% | 0.00% | +100.0% |
| Q2 2020 | $6,505,000 | +213.9% | 368,370 | +25.5% | 0.00% | 0.0% |
| Q1 2020 | $2,072,000 | -45.7% | 293,596 | -45.8% | 0.00% | – |
| Q4 2019 | $3,814,000 | +21.6% | 541,196 | +107.2% | 0.00% | -100.0% |
| Q3 2019 | $3,136,000 | +27.1% | 261,173 | +28.1% | 0.00% | 0.0% |
| Q2 2019 | $2,468,000 | +48.1% | 203,851 | +53.7% | 0.00% | – |
| Q1 2019 | $1,667,000 | +5.2% | 132,644 | -43.7% | 0.00% | – |
| Q4 2018 | $1,584,000 | +30.7% | 235,394 | +99.8% | 0.00% | – |
| Q3 2018 | $1,212,000 | +43.3% | 117,825 | -6.5% | 0.00% | – |
| Q2 2018 | $846,000 | -30.4% | 126,027 | -11.1% | 0.00% | – |
| Q1 2018 | $1,216,000 | -58.2% | 141,684 | +1.2% | 0.00% | -100.0% |
| Q4 2017 | $2,911,000 | +46.1% | 139,977 | +24.0% | 0.00% | 0.0% |
| Q3 2017 | $1,993,000 | +65.0% | 112,842 | +5.6% | 0.00% | – |
| Q2 2017 | $1,208,000 | -6.8% | 106,880 | +5.6% | 0.00% | -100.0% |
| Q1 2017 | $1,296,000 | -40.7% | 101,218 | +1.9% | 0.00% | 0.0% |
| Q4 2016 | $2,185,000 | +11.5% | 99,368 | +7.1% | 0.00% | 0.0% |
| Q3 2016 | $1,960,000 | – | 92,820 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |